TL;DR
This study reveals that the H6N6 avian influenza virus, a low-pathogenic strain with expanding host range, can induce pyroptosis (a form of programmed cell death) in human M1 macrophages. This process, mediated by the NLRP3/caspase-1/GSDMD pathway, leads to the release of inflammatory cytokines, potentially contributing to severe lung inflammation and cytokine storms.
What Problem Does This Paper Address?
Avian influenza viruses (AIVs) pose a significant threat due to their ability to cross species barriers and infect humans, sometimes leading to severe disease and pandemics. While highly pathogenic AIVs like H5N1 and H7N9 are well-known for causing severe illness, the pathogenic mechanisms of less pathogenic strains, such as H6N6, are less understood. H6N6 has shown an increasing ability to infect mammals, raising concerns about human infection. Specifically, it was unclear whether H6N6 could trigger pyroptosis in human lung cells, a process implicated in the dangerous "cytokine storms" seen with other AIVs. This paper addresses this gap by investigating whether H6N6 infection induces pyroptosis in human M1 macrophages, a key immune cell in the lungs, and elucidating the underlying molecular pathway.
Methods
The researchers employed a multi-pronged approach to investigate H6N6-induced pyroptosis:
- Viral Replication and Infection: Human lung tissue explants and human acute monocytic leukemia cell line (THP-1) were used to assess H6N6 virus replication and infection.
- Macrophage Polarization: THP-1 cells were differentiated into M0 macrophages and then polarized into M1 macrophages using phorbol 12-myristate 13-acetate (PMA), lipopolysaccharides (LPS), and interferon-gamma (IFN-γ). This was confirmed by measuring the mRNA expression of M1-associated markers (CXCL-10, TNF-α, COX-2, IL-6) via RT-qPCR.
- Cell Viability and Cytotoxicity Assays: The CCK-8 assay was used to measure M1 macrophage viability after H6N6 infection, and the Lactate Dehydrogenase (LDH) release assay was employed as a biomarker for pyroptosis, indicating plasma membrane damage.
- Morphological Analysis: Scanning Electron Microscopy (SEM) was used to visualize the morphological changes in M1 macrophages infected with H6N6, looking for characteristic signs of pyroptosis like cell swelling and pore formation.
- Molecular Pathway Analysis:
- Gene Expression: RT-qPCR was used to quantify the mRNA expression of key pyroptosis-related genes: NLRP3, caspase-1, and Gasdermin D (GSDMD).
- Protein Expression: Western blot (WB) was performed to detect the protein levels of full-length GSDMD and its cleaved N-terminal fragment (GSDMD-N).
- Cytokine Detection: ELISA was used to measure the release of pro-inflammatory cytokines IL-1β and IL-18 in the supernatant of infected M1 macrophages.
- Pharmacological Inhibition: Specific inhibitors for NLRP3 (MCC950), caspase-1 (AC-YVAD-CMK), and GSDMD (LDC7559) were used to block the pathway and confirm its role in H6N6-induced pyroptosis.
Datasets
Not discussed in the paper. The study primarily uses in vitro cell culture models and human lung tissue explants.
Key Insights and Ideas
- H6N6's Unexpected Pyroptotic Potential: It's significant that a low-pathogenic avian influenza virus (LPAIV) like H6N6 can induce pyroptosis. This challenges the notion that only highly pathogenic strains are capable of such severe inflammatory responses.
- M1 Macrophages as Key Players: The study pinpoints M1 macrophages as a critical target cell for H6N6-induced pyroptosis. Given their role in initiating inflammatory responses, their pyroptosis can significantly amplify inflammation.
- The NLRP3/Caspase-1/GSDMD Axis: The research clearly delineates the canonical pyroptosis pathway (NLRP3 inflammasome activation, caspase-1 cleavage of GSDMD, and subsequent pore formation) as the mechanism by which H6N6 triggers cell death and cytokine release.
- Amplification of Inflammation: The concurrent pyroptosis of M1 macrophages (which already produce pro-inflammatory cytokines) with the release of IL-1β and IL-18 creates a potent inflammatory cascade, potentially leading to a cytokine storm.
- Potential for Novel Therapeutics: Identifying this specific pathway opens doors for developing targeted therapies that could dampen the inflammatory response to H6N6 infections, moving beyond just antiviral treatments.
Key Results
- H6N6 virus effectively replicated in and infected human lung tissue and M1 macrophages.
- H6N6 infection led to increased mRNA expression of NLRP3, caspase-1, and GSDMD in M1 macrophages.
- Protein analysis showed increased levels of cleaved GSDMD (GSDMD-N), a hallmark of pyroptosis.
- H6N6 infection significantly increased the release of pro-inflammatory cytokines IL-1β and IL-18.
- Inhibition of NLRP3, caspase-1, or GSDMD significantly attenuated H6N6-induced pyroptosis markers (LDH release, GSDMD-N levels, and cytokine release).
- SEM revealed morphological changes in infected M1 macrophages consistent with pyroptosis, including cell swelling and pore formation.
Limitations and Future Work
The authors acknowledge several limitations:
- In Vitro Focus: The current study primarily demonstrates H6N6-induced pyroptosis in M1 macrophages in vitro. Future work should explore the in vivo relevance by correlating pyroptosis markers with histopathological indices and inflammation scores in animal models.
- Morphological Quantification: While SEM provided qualitative evidence of pyroptosis, quantitative analysis of pore size and frequency was limited by experimental constraints. Future studies should optimize SEM protocols for better quantification.
- Upstream NLRP3 Activation: The precise molecular mechanisms by which H6N6 activates the NLRP3 inflammasome remain unclear and require further investigation.
- Alternative Pyroptotic Pathways: The study focused on the canonical pathway. Future research should explore other pyroptotic pathways, such as the non-canonical caspase-4/11-mediated and caspase-3/GSDME pathways, and analyze heterogeneity in macrophage subpopulations using single-cell RNA sequencing.
- H6N6 Strain Diversity: The study used a specific H6N6 strain. Given the genetic diversity and varying pathogenicity among H6N6 strains, future work should investigate how different strains might influence pyroptosis induction and disease severity.
- Dose and Time-Course: Further studies are needed to explore a broader range of MOIs and more frequent time points to fully elucidate the kinetic and dose-dependent mechanisms.
Summary updated